Welcome to our dedicated page for Cannabis Bioscience International Holdings news (Ticker: CBIH), a resource for investors and traders seeking the latest updates and insights on Cannabis Bioscience International Holdings stock.
Cannabis Bioscience International Holdings Inc (CBIH) delivers innovative cannabinoid-based therapies through cutting-edge research and strategic intellectual property development. This page provides investors and industry observers with centralized access to official company announcements, regulatory filings, and scientific advancements.
Key resources include: Press releases detailing new patent filings, updates on clinical trial progress, partnership announcements with pharmaceutical entities, and insights into regulatory engagements. Our curated collection ensures stakeholders stay informed about CBIH's pioneering work in cancer treatments, anti-inflammatory solutions, and neurodegenerative disease research.
Bookmark this page for real-time updates on CBIH's OTC market activities, research breakthroughs, and strategic initiatives shaping the future of medical cannabis applications. Regularly refreshed content offers a reliable foundation for informed decision-making without speculative commentary.
Cannabis Bioscience International Holdings (OTCMKTS:CBIH) has initiated a strategic expansion in the cannabis market by applying for important manufacturing, production, and retail licenses. The company has filed for Retail Hemp Registration (#8305) from the Texas Department of State Health Services, along with Initial Food Manufacturer License (#1037264) and Initial Food & Drug Owner application (#1037264).
CBIH is focusing on regulatory compliance while developing projects, refining patent applications, and preparing for clinical data trials. The company aims to introduce new revenue streams through dietary supplements and nutraceuticals, potentially partnering with a national product manufacturer to launch cannabis-based products.
CBIH's strategy aligns with the potential reclassification of cannabis as medicine, positioning the company to capitalize on this shift. The focus remains on developing products as vitamins or nutraceuticals, acknowledging the therapeutic benefits of cannabis while adhering to federal and state regulations.
Since early 2024, Cannabis Bioscience International Holdings (OTCMKTS: CBIH) has been engaging in transformative activities, including mergers, patent registrations, and valuation efforts. The company aims to lead in cannabis medicine by conducting self-driven clinical studies and seizing opportunities from cannabis declassification. CBIH plans to file patents with the USPTO to tap into the U.S. market and collaborate with pharmaceutical companies. Key initiatives include addressing under-researched medical conditions and forming strategic partnerships, such as with VITA Biotech Research, which has provided a $50,000 installment. The company's valuation has reached $2 billion, underscoring its growth and innovative strategies.
Since the beginning of 2024, Cannabis Bioscience International Holdings (OTC Pink: CBIH) has focused on mergers, patent registrations, and valuation. CBIH is emphasizing self-conducted clinical trials to gather evidence for its therapeutic interventions, especially with the potential declassification of cannabis. The company plans to file patents with the USPTO to strengthen its U.S. market presence, targeting collaborations with pharmaceutical companies. CBIH's valuation has reached $2 billion, and its partnership with VITA Biotech Research has advanced its nutraceutical development, securing a $50,000 installment. This partnership also aids in trademark registration for dietary supplements. CBIH aims to address overlooked medical conditions like menopause syndrome and Ewing cancer, seeking sustainable competitive advantage through strategic initiatives.
Cannabis Bioscience International Holdings (OTCMKTS: CBIH) announces its submission of two patents for novel treatment methods targeting breast and pancreatic cancers.
These patents, under legal review, represent the culmination of extensive research aimed at leveraging cannabinoids' antitumor properties. Breast cancer affects one in eight women in the U.S., while pancreatic cancer has a five-year survival rate below 10%.
CBIH plans to expedite innovation, aiming to submit 3-4 patents monthly, targeting conditions like herpes zoster, knee osteoarthritis, and Alzheimer's.
The company is bolstering its research team, notably with Sheila Tarqui, an expert in biology, pharmaceutical chemistry, and public health.
Additionally, CBIH intends to recruit oncology and cardiology specialists to explore the therapeutic potential of cannabinoids in addressing cardiovascular diseases, the leading global cause of death.
CBIH, trading under OTC Pink: CBIH, has announced the submission of two pioneering patents targeting breast and pancreatic cancer treatments. The company aims to leverage the antitumor properties of cannabinoids to create innovative treatments that protect surrounding tissues. With breast cancer affecting 1 in 8 U.S. women and pancreatic cancer having a grim prognosis, these developments are significant. CBIH plans to submit 3-4 additional patents monthly, focusing on conditions like herpes zoster, knee osteoarthritis, and Alzheimer's disease. The company is expanding its research team, including welcoming Sheila Tarqui, an expert in biology and pharmaceutical chemistry. Recruitment efforts also aim to involve oncology and cardiology specialists to explore the therapeutic potential of cannabinoids in cardiovascular diseases.
Cannabis Bioscience International Holdings (OTCMKTS: CBIH) has announced strategic advancements under the leadership of its new Treasurer and Director, John Jones. Mr. Jones has facilitated discussions with a leading company specializing in innovative product and packaging solutions. This potential collaboration aims to leverage the company's expertise in various sectors, including retail, packaging, and distribution, to support CBIH's manufacturing and distribution efforts. The partner company, with over 80 years of experience, could play a pivotal role in converting CBIH's products into revenue streams. Mr. Jones's strategic planning and foresight have positioned CBIH optimally for this potential partnership, which could drive significant growth and industry recognition.
CBIH recently appointed John Jones as Treasurer and Director, unveiling innovative product strategies and potential partnerships. Mr. Jones has initiated discussions with a leading company in product and packaging solutions, positioning CBIH to enhance its manufacturing and distribution capabilities. The prospective partnership could see this entity distributing CBIH's products across sectors like retail and industrial packaging. Mr. Jones emphasized the need for a high-caliber partner to meet and exceed industry standards, potentially converting CBIH's products into revenue streams. The partner, with over 80 years of experience, is one of the largest US distributors, aligning well with CBIH's strategic goals.
Cannabis Bioscience International Holdings (OTC Pink: CBIH) has reached a historic 2 billion dollar valuation, reflecting over 15 years of dedication to medicinal cannabis research. The company emphasizes its commitment to enhancing healthcare standards and promoting cannabinoids as primary treatment options. CEO Dante Picazo shares enthusiasm about future advancements in healthcare. CBIH integrates neuroscience principles to revolutionize medicine and offers groundbreaking solutions globally. The company aims to expand its market presence and innovate new therapeutic alternatives, reaffirming its commitment to excellence in the cannabis industry.
Cannabis Bioscience International Holdings (OTC PINK: CBIH) has been valued at $2 billion following an extensive evaluation by StoneBridge Advisory. This valuation underscores CBIH's strong market presence, innovative product offerings, and solid business framework. The assessment considered CBIH's financial metrics, market penetration, industry competition, and strategic planning. CBIH's team includes experts in various fields, contributing to a diversified portfolio of therapies and solutions addressing global health issues. This valuation primes CBIH for strategic alliances, investments, and expansion in the cannabis bioscience sector.
Vita Biotech Research has partnered with Cannabis Bioscience International Holdings (OTCMKTS: CBIH) to fund CBIH's clinical studies, enhancing data integrity and speeding up progress. Vita Biotech will act as a financial subsidiary, supporting data collection trials important for evaluating CBIH's formulations. This collaboration allows CBIH to isolate each medical formulation into a unique legal entity, a risk management strategy that simplifies financing and partnerships. Texas was chosen for patent housing due to its favorable judicial environment. The partnership aims to improve statistical significance, uphold ethical standards, and bolster CBIH's research credibility.
